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Abstract
Background: Representative population-based data on the epidemiology of pulmonary non-tuberculous
mycobacterial (PNTM) infections in Europe are limited. However, these data are needed in order to optimise patient
care and to facilitate the allocation of healthcare resources. The aim of the present study was to investigate the
current burden and the trends of PNTM infection-associated hospitalisations in Germany.
Methods: International Classification of Diseases, 10th revision (ICD-10) discharge diagnosis codes were extracted
from the official nationwide diagnosis-related groups (DRG) hospital statistics in order to identify PNTM
infection-associated hospitalisations (ICD-10 code A31.0) between 2005 and 2011. Poisson log-linear regression
analysis was used to assess the significance of trends.
Results: Overall, 5,959 records with PNTM infection as any hospital discharge diagnosis were extracted from more
than 125 million hospitalisations. The average annual age-adjusted rate was 0.91 hospitalisations per 100,000
population. Hospitalisation rates increased during the study period for both males and females, with the highest
rate of 3.0 hospitalisations per 100,000 population among elderly men, but the most pronounced average increase
of 6.4%/year among females, particularly those of young and middle age, and hospitalisations associated with cystic
fibrosis. Overall, chronic obstructive pulmonary disease (COPD) was the most frequent PNTM infection-associated
condition in 28.9% of hospitalisations and also showed a significant average annual increase of 4.8%.
Conclusions: The prevalence of PNTM infection-associated hospitalisations is steadily increasing in Germany. COPD
is currently the most important associated condition. Our population-based study provides evidence of a changing
epidemiology of PNTM infections and highlights emerging clinical implications.
Keywords: Atypical mycobacterial infection, Bronchiectasis, Clinical epidemiology, COPD epidemiology,
Cystic fibrosis, Health services research, International classification of diseases, Mycobacterium avium complex,
Non-tuberculous mycobacteria, Tuberculosis
Background
Non-tuberculous mycobacteria (NTM) are ubiquitous
environmental and biologically diverse micro-organisms,
some of which are associated with chronic and progres-
sive pulmonary infections in susceptible individuals
[1,2]. In general, Mycobacterium avium complex (MAC)
is considered the most common causative agent of pul-
monary NTM (PNTM) infection worldwide [3-6].
Recent epidemiologic data suggest that both the inci-
dence and the prevalence of NTM infections are increas-
ing worldwide [5,7-12]. Furthermore, there is growing
evidence that the epidemiology of PNTM infections is
changing, with immunocompetent subjects suffering from
pre-existing structural lung disease and adults aged ≥50
years with a substantial proportion of never-smoking
females without previous lung disease being increasingly
reported from outside Europe [5,7,13,14]. Most of these
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studies were either solely laboratory-based or used the
frequency of NTM isolates from clinical specimens in
order to determine prevalence and to reason the sig-
nificance of NTM infection in conjunction with clinical
and radiological data according to the American Tho-
racic Society (ATS) and Infectious Diseases Society of
America (IDSA) statement on the diagnosis of NTM
disease [3,7,10,11,13-15].
However, while representative population-based data for
Europe are limited [11,15], the epidemiology of PNTM in-
fections in Germany is largely unknown. In Germany,
population-based data regarding hospitalisations are avail-
able at a federal level. Although primarily used for the bill-
ing of health services, some important epidemiological
evidence has originated from the analysis of International
Classification of Diseases hospital discharge diagnosis
codes and health insurance claims [9,16].
Epidemiological and health services research on PNTM
infections is required in order to optimise patient care and
to inform health policy. The aim of the present study was
to provide an overview of the current burden and show




The present study used data from the official nationwide
diagnosis-related groups (DRG) hospital statistics, which
are publicly accessible and provided by the Federal Stat-
istical Office together with the Federal Health Monitor-
ing Information System [17,18]. We extracted records
for which the four-digit International Classification of
Diseases, 10th revision (ICD-10) code A31.0, pulmonary
mycobacterial infection (by definition including infection
due to Mycobacterium avium, M. intracellulare and M.
kansasii) within the three-digit category A31 (infection due
to mycobacteria other than M. tuberculosis complex and
M. leprae) was listed as any hospital discharge diagnosis.
All German hospitals using DRG billing of medical
services are legally obligated to transmit this data in re-
sponse to an annual written survey. Consequently, hos-
pitals for prevention, rehabilitation, mental and mood
disorders as well as day care units were not included in
our analysis. ICD-10 was introduced in Germany in
2000. Since 2005, all associated secondary ICD-10 hos-
pital discharge codes are additionally transmitted to the
Federal Statistical Office. In general, primary ICD-10
diagnosis codes are regarded as the principal condition
identified during hospitalisation, while secondary codes
indicate associated or contributing conditions (comor-
bidities and/or complications). De-identified DRG diag-
nosis data were provided for the whole of Germany as
absolute numbers stratified by age groups, sex and year of
diagnosis. Additional variables included associated primary
and secondary conditions as indicated by four-digit ICD-
10 codes, overall length of hospital stay (LOS) as well
as nationwide and in-hospital mortality data regarding
PNTM infection as the primary diagnosis. For comparison,
data regarding the overall LOS were analysed for all
hospitalisations regardless of the primary ICD-10 code
as well as ICD-10 category J44 (other chronic obstructive
pulmonary disease, COPD). Data on PNTM infection as
a cause of death are based on the official causes of death
statistics from the Federal Statistical Office [18]. The data
are acquired within an annual census from mandatory
death certificates and statistical bulletins of mortality using
the ICD-10. However, as in many other countries, NTM
disease is not a notifiable condition in Germany.
Statistical analysis
Analysis comprised all hospitalisations with PNTM in-
fection as either a primary or a secondary hospital dis-
charge diagnosis from 2005 through 2011. Official German
census age- and sex-specific population data were used as
the denominator for all calculations [18]. Age adjustment
was performed by the direct method in order to control
for different age distributions across Germany and to allow
for comparison between different years. Age-adjusted hos-
pitalisation rates were estimated using the latest available
German Census Standard Population as the reference
population. The significance of trends was calculated by
Poisson log-linear regression analysis. Standard errors were
scaled using Pearson’s chi-square statistics in order to ac-
count for overdispersion. Wald statistics and bootstrapping
were used to estimate p values and 95% confidence inter-
vals (CI), respectively. Continuous data were checked for
normal distribution using the Kolmogorov-Smirnov test
before calculating means. Statistical significance was set to
p<0.05. Accordingly, differences were considered statisti-
cally significant if 95% CIs were not overlapping. Moreover,
the annual percentage change (APC) of PNTM infection-
associated hospitalisations was calculated. Associated diag-
noses were analysed and the APC of the rate of associated
primary and secondary diagnoses per 1000 hospitalisations
with any diagnosis of PNTM infection was estimated. Data
analysis was performed using IBM SPSS Statistics, version
20 (IBM Corp., New York, NY).
Study approval and funding
Institutional review board approval and patient consent
were not required as this study is a secondary analysis of
an anonymous and publicly accessible database. There
was no external funding for this study.
Results
Population, hospitals and hospitalisations
From 2005 to 2011, the average annual German popula-
tion was 82.1 million, ranging from 82.4 million in 2005
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to 81.1 million in 2011. During this period, on average
1,673 (95% CI 1,633–1,719) hospitals were subject to
DRG billing of medical services, with a steady decline
from 1,770 to 1,601 hospitals. The average overall num-
ber of hospitals in Germany was 2,087 (95% CI 2,067–
2,108). Hence, 80% of all hospitals were included in our
analysis. On average, there were 17.9 (95% CI 17.4–18.3)
million hospitalisations per year, with a steady increase
from 17.0 million to 18.8 million.
Burden of PNTM infection as a hospital
discharge diagnosis
From 2005 to 2011, a total of 125.2 million hospitalisations
were analysed over an observational period of 574.4 million
person-years. Overall, 3,102 hospitalisations with PNTM
infections as the primary hospital discharge diagnosis and
5,959 hospitalisations as either a primary or a secondary
diagnosis were identified (Figure 1). Of those, 3,607 hos-
pitalisations (61%) were among males and 3,818 (64%)
were among subjects aged ≥55 years. The overall average
annual age-adjusted hospitalisation rate was 0.91 (95% CI
0.83–0.99) per 100,000 population. This rate was signifi-
cantly higher among males (1.06; 95% CI 0.97–1.14) com-
pared to females (0.74; 95% CI 0.67–0.82). However, there
was considerable variation with age, with the highest age-
specific hospitalisation rate of 3.0/100,000 population
among elderly men (Figure 2).
Trends of PNTM infections as a hospital
discharge diagnosis
The annual number of all PNTM infection-associated
hospitalisations ranged from 665 in 2005 to 1,039 in 2011.
Accordingly, the annual proportion of PNTM infection-
associated hospitalisations among all hospitalisations steadi-
ly increased from 0.0039% to 0.0055% during this
period, with an average annual increase of 4.9% (95%
CI 3.6–6.2; p<0.00001). The overall age-adjusted rate of
PNTM infection-associated hospitalisations increased sig-
nificantly from 0.73 to 1.09 per 100,000 population, with
an average increase of 5.9% (95% CI 4.7–7.0; p<0.00001)
per year. Among males, the annual age-adjusted preva-
lence increased from 0.88 to 1.23 per 100,000 population.
This upward trend was even more pronounced among fe-
males, with an increase of 0.57 to 0.91 per 100,000 popu-
lation (Table 1; Figure 2).
Burden and trends of associated diagnoses
Secondary ICD-10 codes were available for analysis from
all hospitalisations with a primary diagnosis of PNTM
infection. Table 2 lists conditions with frequencies >1%
which are commonly considered associated with and/or
predisposing to PNTM infections, while Table 3 shows
the ten most frequent comorbidities considered unre-
lated to PNTM infections.
In addition, this permitted the analysis of associated
primary diagnoses when PNTM infection was the sec-
ondary diagnosis (Table 4) as well as the analysis of the
APC of the overall rate of associated primary and sec-
ondary diagnoses (Figure 3).
The average number of secondary diagnoses per pri-
mary diagnosis of PNTM infection was 5.5 (95% CI 5.2–
5.7), with an average increase of 2.9%/year (95% CI 1.7–
4.1; p<0.00001), ranging from 5.0 in 2005 to 6.2 in 2011.
Chronic lower respiratory diseases (ICD-10 codes J40–
J47) and, in particular, COPD and emphysema (ICD-10
codes J43 and J44, analysed as one entity) were the pre-
dominant secondary diagnosis of hospitalisations with
PNTM infection as the primary diagnosis, respectively
(Table 2). Among all records with PNTM infection as
any diagnosis, PNTM infection itself was the most fre-
quent primary diagnosis, followed by chronic lower re-
spiratory diseases, COPD and emphysema and a variety
of other primary diagnoses (Table 4).
Figure 1 Data flow and data analysis diagram. APC = annual
percentage change; PNTM = pulmonary non-tuberculous mycobacterial.
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Accordingly, chronic lower respiratory diseases as well
as COPD and emphysema had by far the highest overall
rates of 361 and 289 associated diagnoses per 1,000 hos-
pitalisations with any diagnosis of PNTM infection, re-
spectively. Figure 3 shows the downward and upward
trends of the rates of PNTM infection-associated diag-
noses with significant average annual changes.
Length of hospitalisation and mortality
The mean overall LOS per hospitalisation with PNTM
infection as the primary diagnosis of 18.3 (95% CI 16.8–
20.0) days was significantly longer than the LOS for
COPD as a primary diagnosis (ICD-10 category J44; 10.4
(95% CI 10.0–10.7) days and for all hospitalisations (all
ICD-10 codes; mean 8.1 (95% CI 7.9–8.4) days). Between
2005 and 2011, the LOS showed a significant downward
trend for PNTM infections (−5.0%; 95% CI −7.8–(−2.2);
p = 0.0005), COPD (−2.2%; 95% CI −2.5–(−1.8); p<0.00001)
as well as all hospitalisations (−1.8%; 95% CI −1.9–(−1.6);
p<0.00001). According to the causes in German death
statistics, there were only 16 notified deaths due to PNTM
infection among ten males and six females between 2005
A
B
Figure 2 Age-specific and age-adjusted hospitalisation rate. (A) Average annual age-specific hospitalisation rate and (B) annual age-adjusted
hospitalisation rate of pulmonary non-tuberculous mycobacterial infection as any hospital discharge diagnoses, by age group, sex and year.
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and 2011. Of those deceased, ten subjects (63%) were aged
≥65 years. Notably, none of those 16 deaths occurred inside
the hospital.
Discussion
Our study provides a detailed picture of PNTM infection-
associated hospitalisations in Germany and emphasises
the considerable interaction with chronic respiratory dis-
eases, particularly COPD as the most frequent associated
condition. Between 2005 and 2011, elderly men had the
highest age-specific hospitalisation rate. However, while
the prevalence of PNTM infection-associated hospital-
isations increased significantly and regardless of the in-
creasing overall number of hospitalisations for both sexes,
it showed the most pronounced increases among females,
especially those of young and middle age, and hospitali-
sations associated with cystic fibrosis (CF). These findings
may be relevant to patient care and the allocation of re-
sources in healthcare.
Population-based data on the epidemiology of PNTM
infections in Europe are limited [11,15]. Two recent stud-
ies from France and Denmark, which analysed periods
from 2001 to 2003 and from 1997 to 2008 and linked
NTM isolates from respiratory specimens to population-
based clinical data, found similar average annual rates
of 0.7 and 1.1 PNTM infection per 100,000 population
[11,15]. However, the incidence remained unchanged dur-
ing the respective study periods. In this concern, our re-
sults are consistent with the upward trends of PNTM
infections from other laboratory- and population-based
studies around the world [8,13,16,19-21]. Our overall aver-
age annual age-adjusted hospitalisation rate of 0.9 PNTM
infections per 100,000 population as well as the average
age-adjusted increase of 6%/year is slightly lower, but com-
parable to the findings of a recent study from the United
States (US) [9]. However, in line with other European
studies that have shown consistently lower rates of PNTM
than in North American studies [3,11,14,15], age and sex
specific hospitalisation rates among elderly men and
women were considerably lower in our study than in the
aforementioned US study by Billinger and colleagues [9].
Furthermore, in agreement with other US studies we
found that the prevalence of PNTM infection was most
significantly increasing among females [3,9,13,16]. In fact,
males carried the major burden of PNTM-associated
hospitalisations in our study, whereas elderly women
with nodular bronchiectatic disease have been considered
as the predominant patient population outside Europe
[3,14,16,22]. This finding supports the existence of a
unique epidemiology of PNTM infections in accordance
with the distinct distribution of NTM species isolated
from respiratory samples within Europe and recent reports
from other European countries [6,11,15,19,20,23], where
PNTM infections appear to be . However, it remains to
be studied whether changing host factors or a changing
NTM species distribution over time account for these
observations [6].
Notably, we observed a significant decline of immuno-
deficiencies, tuberculosis (TB), alcohol-related disorders
and influenza and pneumonia among PNTM infection-
associated hospitalisations. In line with previous studies
observing an increase in PNTM infections, the incidence
of TB and with it the number of TB-associated hospi-
talisations declined steadily in Germany during the study
period [8,12,17,21,24,25]. However, in contrast to reports
from the US and Canada [3,13,14,21], the incidence of
TB may still outrange that of PNTM infections in most
European countries [25].
The present study is a nationally representative
population-based analysis of the burden and trends among
almost 6,000 PNTM infection-associated hospitalisations,
including 80% of hospitals across the country and >125
million hospitalisations over a 7-year period. However,
our study has some inherent limitations. Firstly, ICD-10
Table 1 Average annual percentage change of pulmonary non-tuberculous mycobacterial infection-associated
hospitalisations, stratified by sex and age group
Males Females
Age group (years) Annual % change 95% CI (Wald) p Value Annual % change 95% CI (Wald) p Value
0–24* 11.2 −1.5 to 24.0 0.085 13.7 5.9 to 22.1 0.0004
25–34* −0.3 −5.3 to 4.7 0.90 −8.3 −20.3 to 3.8 0.18
35–44* −0.5 −11.6 to 10.6 0.93 16.7 8.3 to 25.8 0.00005
45–54* 2.6 −1.2 to 6.5 0.18 2.3 −4.7 to 9.2 0.53
55–64* 5.7 3.2 to 8.3 <0.00001 8.9 4.5 to 13.4 <0.00001
65–74* 9.8 5.5 to 14.2 <0.00001 9.9 3.0 to 17.2 0.004
75–84* 6.9 2.9 to 11.1 0.0007 3.8 −3.2 to 10.9 0.29
≥85* 4.5 −12.3 to 21.3 0.60 −8.8 −18.4 to 0.8 0.072
All ages# 5.3 4.0 to 6.6 <0.00001 6.4 4.1 to 8.7 <0.00001
*Referring to the age-specific hospitalisation rate per 100,000 population. #Referring to the age-adjusted hospitalisation rate per 100,000 population.
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diagnosis codes are primarily used for reimbursement pur-
poses and only secondarily for epidemiological research.
They may be subject to potential sources of errors, lack
validation for PNTM infections and, in general, are con-
sidered to have high specificity, but only moderate sensi-
tivity, thus being prone to an underestimation of disease
prevalence [9,20,26]. Secondly, the diagnosis of PNTM in-
fection did not require compliance with the ATS/IDSA
diagnostic criteria for NTM disease [1]. Details on isolated
mycobacterial species and disease presentations were un-
available. However, the fact that PNTM infection itself was
the primary diagnosis in >50% of hospitalisations and se-
vere complications like respiratory failure were frequent
and significantly increasing over time suggests clinically
relevant disease in the majority of hospitalisations. Thirdly,
we were unable to account for readmissions, which may
have had an impact on hospitalisation rates, though a sub-
stantial overestimation appears unlikely. Fourthly, several
Table 2 Conditions commonly associated with and/or predisposing to pulmonary non-tuberculous mycobacterial (PNTM)
infection among secondary diagnoses when PNTM infection is the primary hospital discharge diagnosis (n=3,102)
ICD-10 Secondary diagnosis Frequency Percentage
J40–J47 Chronic lower respiratory diseases 1,671 53.9
J43, J44 COPD and emphysema 1,297 41.8
J96 Respiratory failure 633 20.4
Z29.0 Isolation care 533 17.2
R64 Cachexia 341 11.0
F17 Nicotine dependence 334 10.8
J09–J18 Influenza and pneumonia 300 9.7
J47 Bronchiectasis 199 6.4
B37 Candidiasis 189 6.1
B20–B24 Human immunodeficiency virus 172 5.5
B96.2 Escherichia coli as a causative agent 150 4.8
R04.2 Haemoptysis 135 4.4
A15–A19 Tuberculosis 125 4.0
F10 Alcohol-related disorders 116 3.7
I27 Pulmonary heart diseases 116 3.7
D38 Airway or chest neoplasm of uncertain
or unknown behaviour
114 3.7
Z90.2 Acquired absence of (part of) lung 114 3.7
J84 Interstitial lung disease 112 3.6
U82.2 Resistance to one or more first-line
antimycobacterial drugs
86 2.8
K21 Gastroesophageal reflux disease 85 2.7
J20–J22 Acute bronchitis and bronchiolitis 81 2.6
B90 Sequelae of tuberculosis 80 2.6
J90–J91 Pleural effusion 78 2.5
J60–J65 Pneumoconioses 72 2.3
M05–M06 Rheumatoid arthritis 70 2.3
B96.5 Pseudomonas aeruginosa as a causative agent 68 2.2
K50–K52 Inflammatory bowel diseases 67 2.2
B44 Aspergillosis 56 1.8
Z94 Transplanted organ or tissue status 54 1.7
B95.6 Staphylococcus aureus as a causative agent 51 1.6
A31.1–A31.9 Other non-tuberculous mycobacterial infections 49 1.6
C34 Lung cancer 49 1.6
D80–D84 Primary immunodeficiencies 41 1.3
COPD = chronic obstructive pulmonary disease; ICD-10 = International Classification of Diseases, 10th revision.
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previous studies have suggested that the epidemiology of
PNTM infections may be influenced by environmental,
geographical and sociodemographic patterns [22,24,27,28].
However, we did not analyse the data stratified for individ-
ual federal states or urban and rural areas, mainly due to
the potential bias related to regional differences of health
care utilisation of medical services, and the unavailability
of information on NTM species. Finally, our results apply
to hospitalised populations only. PNTM infections are
chronic in nature and usually require long-term follow-up
care in the outpatient setting, where disease prevalence is
likely different. A recent report on patient-centred care in
outpatient respiratory medicine, which was based upon
the billing data of 30 representative German private re-
spiratory practices in 2010, showed that ICD-10 category
A31 (infection due to other mycobacteria) accounted for
on average 0.058% of outpatient diagnoses and corres-
pondingly roughly 1,850 consultations [29]. Moreover, the
fact that none of the few deaths occurred during hospital-
isation, further emphasises that the major burden of dis-
ease is managed out-of-hospital. Therefore, our data are
likely to underestimate the overall burden of PNTM infec-
tions. However, as data are limited, our results are the best
currently available surrogate for the epidemiological trends
of PNTM infections across Germany.
Altogether, the reasons for increases in PNTM cases
are unknown. Increasing hospitalisation rates do not ne-
cessarily indicate increasing true incidence or prevalence
of PNTM infections. They may rather be attributable to
advances in laboratory culture and molecular speciation
methods, increasing awareness, increasing environmen-
tal exposure, decreasing immunity to mycobacteria and/
or aging and increasingly prevalent susceptible popula-
tions [4,10,12,24]. In this respect, our findings affirm the
close link between PNTM infection and COPD, which
has also been observed by others [11,13,14]. A recent
Danish population-based case–control study demonstrated
that chronic respiratory disease, particularly COPD, is a
strong risk factor for PNTM disease [23]. On the other
hand, a Canadian study found that the increase in pulmo-
nary MAC disease was likely multifactorial and could not
be explained exclusively by population aging, COPD and
other risk factors [22]. Our finding that hospitalisation
rates were not continuously increasing with age is contrary
to recent studies from the US and Canada, which found
the highest rates among the very advanced age group
[9,13,22], and argues against more severe disease and fre-
quent readmissions in this age group. It may rather indi-
cate age-related differences regarding the access to health
services and suggest that PNTM infections are still under-
diagnosed during hospitalisations of the very advanced age
group in Germany. The increasing number of unrelated
comorbidities, along with the upward trend regarding the
average number of secondary diagnoses per primary diag-
nosis of PNTM infection, may reflect the increasingly aged
and comorbid population during the study period. This is
supported by the fact that both the average age of hos-
pitalised subjects and the average number of secondary
diagnoses per case were steadily increasing in general for
hospitalisations during the study period (from 52.5 to 54.6
years and from 3.9 to 4.8 secondary diagnoses between
2005 and 2011, respectively). Moreover, the observation
that cachexia, defined as a body mass index <18.5 kg/m2
according to common DRG coding guidelines, was a fre-
quent secondary condition in 11% of hospitalisations with
PNTM infection as the primary diagnosis supports the ex-
istence of a distinct morphotype in a subset of patients, as
Table 3 Most frequent comorbidities unrelated to
pulmonary non-tuberculous mycobacterial (PNTM)
infections among secondary diagnoses when PNTM
infection is the primary hospital diagnosis (n=3,102)
ICD-10 Secondary diagnosis Frequency Percentage
I10 Primary hypertension 744 24.0
E87 Disorders of water, electrolyte
and acid–base balance
324 10.4
I25 Coronary artery disease 304 9.8
E11 Diabetes mellitus type 2 223 7.2
I11 Hypertensive heart disease 223 7.2
I48 Atrial flutter or fibrillation 201 6.5
I50 Congestive heart failure 198 6.4
M80–M81 Osteoporosis with or without
pathological fracture
169 5.4
N18 Chronic kidney disease 165 5.3
E03 Hypothyroidism 148 4.8
ICD-10 = International Classification of Diseases, 10th revision.
Table 4 Primary diagnoses among hospitalisations with
pulmonary non-tuberculous mycobacterial infection as
any diagnosis




J40–J47 Chronic lower respiratory diseases 482 8.1
J43, J44 COPD and emphysema 423 7.1
J09–J18 Influenza and pneumonia 234 3.9
C34 Lung cancer 206 3.5
A15–A19 Tuberculosis 133 2.2
E84 Cystic Fibrosis 125 2.1
B20–B24 Human immunodeficiency virus 84 1.4





COPD = chronic obstructive pulmonary disease; ICD-10 = International
Classification of Diseases, 10th revision.
Ringshausen et al. BMC Infectious Diseases 2013, 13:231 Page 7 of 10
http://www.biomedcentral.com/1471-2334/13/231
recently suggested by Kim and colleagues [30]. In this study,
respective subjects were taller and leaner than controls and
had high rates of CF transmembrane conductance regulator
(CFTR) mutations in 36%.
Our findings have several important implications. Al-
though we were unable to estimate the costs for hos-
pitalisations associated with PNTM infection, our data
on the mean LOS confirm that PNTM infections repre-
sent an underappreciated economic healthcare burden,
with considerable associated treatment costs comparable
to that of other chronic infectious diseases [31]. Further-
more, the liaison between PNTM infection and chronic
respiratory diseases like COPD, bronchiectasis and CF,
which were all significantly increasing as associated con-
ditions during the study period, calls for caution regard-
ing the increasingly broad use of macrolide antibiotics as
an adjunct immunomodulatory treatment [32-34]. It has
been shown that macrolides block autophagy and inhibit
the intracellular killing of mycobacteria [35]. As a conse-
quence, their chronic use may hypothetically predispose
to PNTM infection and, moreover, promote the emer-
gence of macrolide resistance, which may be associated
with worse outcomes [1,35]. A novel finding from our
study is that young and middle-aged females showed the
most pronounced increases of average age-specific hospi-
talisation rates of up to 17%/year. This observation may
highlight the importance of genetic susceptibility, particu-
larly CFTR mutations, and warrant extensive work-up and
continued surveillance of these patients. Lastly, it is im-
portant to note that our results may not fully apply to
other European countries and settings.
Conclusions
The present study provides evidence for a unique, though
changing epidemiology of PNTM infection-associated hos-
pitalisations in Germany. However, given the rarity of
PNTM infections multinational clinical research collabora-
tions like the Non-tuberculous Mycobacteria Network
European Trialsgroup (NTM-NET) are needed for future
and prospective research on the epidemiology of PNTM
infections across Europe and beyond.
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